Non-Insulin Therapies for Diabetes Market To Register a Hugh Growth In Healthcare Industry by 2026 With AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hoffmann-La Roche Ltd.
Download PDF Brochure of This Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/2042
The global economic burden of diabetes is high and is expected to substantially increase over the forecast period. According to the American Diabetes Association research in March 2018, the total costs of diagnosed diabetes have risen to US$ 327 billion in 2017 from US$ 245 billion in 2012. Therefore, non-insulin therapies for diabetes market is expected to witness growth in the near future.
Moreover, companies are launching new products and combination therapies in the market, which is expected to drive growth of the global non-insulin therapies for diabetes market. For instance, in 2017, the Food and Drug Administration (FDA) approved Novo Nordisk’s Ozempic (semiglutide), which is once a week GLP-1 analog, would increase the patient compliance. In December 2017, FDA approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor called ertugliflozin (Steglatro), which is jointly developed by the Merck & Co. and Pfizer Inc. and in January 2018, the European Medicines Agency (EMA) granted approval for the same in Europe.
Increasing global incidence and prevalence of diabetes is expected to fuel growth of the non-insulin therapies for diabetes market. Non-insulin therapies are mainly used in type 2 diabetes, which accounts for around 90% of the global diabetes cases. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, worldwide prevalence of diabetic patients was around 425 million, of which around 400 million patients were suffering from type 2 diabetes. As per the World Health Organization (WHO) 2017 report, diabetes is one of the top 3 causes of death among non-communicable diseases worldwide, with 114.4 million cases in China, 72.9 million cases in India, and 30.2 million cases in the U.S.
Request For A Sample Copy of This Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2042
Non-insulin Therapies for Diabetes Market: Regional Insights
On the basis of region, the global non-insulin therapies for diabetes market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to drive growth of the non-insulin therapies for diabetes market due to highest diabetes expenditure in the U.S. According to the International Diabetes Federation (IDF), in 2017, around 17,100 new cases of diabetes were detected in the U.S. Asia Pacific is one of the most lucrative region due to increased diabetes burden in China and India, collectively having over 180 million patients suffering from diabetes. According to the American Diabetes Association (ADA), rising incidence of type 2 diabetes in South Asia is likely to be over 150% between 2000 and 2035.
Non-insulin Therapies for Diabetes Market: Competitive Landscape
Key players operating in the global non-insulin therapies for diabetes market include AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, and Takeda Pharmaceuticals.
Major players are increasingly targeting the newer class of drugs such as GLP-1 analogs or SGLT2. SGLT 2 inhibitors have been approved for use, as a treatment for diabetes since 2013. Most of the drugs under SGL2 inhibitors such as Dapagliflozin, Canagliflozin, and Empagliflozin were launched after 2013. However, intense competition in the market could make it difficult for one particular company to grab larger market share in the non-insulin therapies for diabetes market.
Request For Customization Of This Research Report : https://www.coherentmarketinsights.com/insight/request-customization/2042
Non-insulin Therapies for Diabetes Market: Taxonomy
On The Basis Of Drug Class, the global non-insulin therapies for diabetes market is segmented into:
Sodium-glucose co-transporter-2 (SGLT2) inhibitors
On The Basis Of Route Of Administration, the global non-insulin therapies for diabetes market is segmented into:
On The Basis Of Distribution Channel, the global non-insulin therapies for diabetes market is segmented into:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Insulin Therapies for Diabetes Market To Register a Hugh Growth In Healthcare Industry by 2026 With AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hoffmann-La Roche Ltd. here
News-ID: 1429535 • Views: 977
More Releases from Coherent Market Insights - Biotechnology
Wearable Patch Market 2030 Emerging Trends and Global Demand During the COVID-19 …
Coherent Market Insights published a report, titled,"Wearable Patch Market, by Technology (Connected and Regular), by Application (Monitoring, Drug Delivery, and Diagnostics), by End User (Healthcare and Fitness & Sports), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027." Wearable patches are used for monitoring and diagnosis of chronic diseases. Increasing prevalence of diseases such as atrial
Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast P …
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used
Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness
Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. Free Request Sample Copy
More Releases for Diabetes
Global Diabetes Industry
Global Diabetes Industry Market Insight Global diabetes market is expected to grow at a CAGR of 7.9% percent for the forecasted period of 2016-2021. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 9%. Some of the top selling
27th European Diabetes Congress
Rising awareness, new technologies and practical approaches within the field of diabetes and endocrine disorders in world’s leading diabetes Conferences One in eight ladies can develop a diabetes disorder throughout her lifespan. And, the amount of individuals affected by diabetes disorders continues to rise every year. However the larger drawback is that almost 60 minutes of those individuals are fully unaware of their condition as well as a way to heal
27th European Diabetes Congress
We would like to invite your team as a Speakers/Delegates. On behalf of Organizing Committee, we take this opportunity in extending a warm and cordial welcome to you to be part of “27th European Diabetes Congress”, held conjointly with multifarious scientific associations, eminent researchers and scholars from all around the globe during June 20-21, 2018 at Rome, Italy. It is an immense pleasure and privilege having you here with us
Global Diabetes Management Devices Market
ReportsWorldwide has announced the addition of a new report title Global Diabetes Management Devices Market to its growing collection of premium market research reports. The global market for diabetes management devices is a substantial, highly competitive market driven by highly sophisticated, evolving technology, particularly in the insulin pump/artificial pancreas and CGM area. The report provides the following useful information: • diabetes overview • key statistics on diabetes prevalence in major regions in the world • medical device product
Non Invasive Diabetes Therapy Market
The role of non-invasive therapy for diabetes market has been on a positive growth path in healthcare industry since 2014. Though the non-invasive therapy concept was brought way back in 1980, the market has not gained much attention leading to development of fewer such devices. DexCom's seven system and Medtronic's Guardian real-time glucose monitoring system are two such products developed and marketed worldwide. The influx of non-invasive therapy has reinforced
Diabetes Gastroparesis Market grows with rising prevalence of diabetes
Diabetes type 1 and type 2 are one of the most common chronic diseases prevalent in the world, affecting millions of people. One of the disorders associated with diabetes type 1 and type 2 is gastroparesis, which is characterized by the delayed emptying of the stomach. One of the major causes of gastroparesis is damage to the vagus nerve, reducing the mobility of the stomach contents. Diabetic neuropathy affects the